MedPage Today reported on a new, retrospective study involving Kyprolis over the weekend. It makes my myeloma specialist, Dr. Tricot, look pretty smart for using Kyprolis as part of my three drug post transplant consolidation therapy. According to the study, close to 50% of patients who have previously used Velcade and/or Revlimid responded to Kyprolis
Say it ain't so! Don't get diagnosed with multiple myeloma in England, Northern Ireland, Scotland or Wales. New austerity measures could result in an early death sentence for our brothers and sisters with myeloma in the UK. I wasn't planning to write about this today, but I became so upset after reading an article on
My red blood counts crashed over the past 24 hours; it's taken me some time to adjust. Hard to say if Cytoxan, Kyprolis or the combination of the two is responsible. But I'm doing better now--and I have ten days to recover before my next therapy cycle. Looks like I missed some significant news while
I received some good news from Eliza Schleifstein with Cegene. She passed along this information for me to share: Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has expanded the existing indication for REVLIMID® (lenalidomide) in combination with dexamethasone to include patients newly diagnosed with multiple myeloma. The treatment is
No ASCO blockbusters. Some significant data was presented. But as I mentioned yesterday, nothing time sensitive. So today I would like to write briefly about what could be a life changing meeting tomorrow at Mayo Clinic. OK, I'll admit it. I'm apprehensive about my appointment with my new myeloma specialist, Dr. Roy. My first impressions
As I mentioned in a post on May 21, we have planned three moving days. The first was a preliminary move to get needed tools, bedding and that sort of thing over to the new "fixer" on Fernandina Beach. Today's is "the big one;" three strong guys and a big truck. And the third? My
It's an awesome Friday morning! I'm both delighted and relieved. Delighted that our University of Wisconsin basketball team won again last night, advancing to the NCAA Tournament's Elite Eight; the Badgers play Arizona Saturday to see which team will advance to the Final Four. And I'm relieved to report even better news: I learned yesterday
I concluded Saturday's post this way: "Tomorrow I will reveal what my topnotch medical team decided to try and knock my myeloma back into submission. Here's a hint: I was pleasantly surprised; it was a unanimous decision!" In past posts--and this month's Myeloma Beacon column--I had expressed concern that my healthcare team and I were
I feel great! Energy level is good. I've even been experiencing less bone pain, allowing me to cut back on my pain meds. So why am I so apprehensive about a tiny prick in the arm today? All part of the routine surrounding my six week treatment cycle; once a week Velcade, sub-q with a
I met with my medical oncologist, Dr. Vikas Malhotra, for the first time since last month's relapse today. He reviewed my test results, including the MRI of my left hip. It reminded me why working together as a team is so important. I felt that Dr. Malhotra and his physicians assistant, Ann, made some innovative
Looking back, I experienced mild peripheral neuropathy (PN) even before I was diagnosed. My hands would shake when I tried to write. And I experienced some tingling in my feet. But within six months of using Revlimid, my PN became a significant issue. My feet began to tingle 24/7, and my hands became stiff and
Before I get started this morning, I wanted to share some sage advice that I received from one of my regular readers after they learned I was struggling with my father's life nearing the end: My father died suddenly a few weeks before his 39th birthday. I was eighteen at the time, my sister 11.
This headline on a well known medical website made me laugh: From ASCO – Revlimid May be Effective for Newly Diagnosed Multiple Myeloma Really? Docs have been prescribing Revlimid to their newly diagnosed patients since late 2006! But the keystone novel therapy has never been officially approved for use in new patients by the FDA.
For me, one of the most frustrating part of reading abstracts and following oral presentation myeloma results at meetings like ASCO and ASH is that you are rarely comparing apples to apples. Are study subjects "heavily pretreated," "refractory," or both. And what about "relapsed?" Sometimes some of these terms are used interchangeably. Sometimes not. Let
I stuck with the original heading for the third installment of my three part investigative expose'. But today's post could have been titled, "Different shades of grey." Pomalidomide's development was shaped by a convoluted system that does a poor job balancing patient need with investor returns. But I'm getting ahead of myself. Yesterday I promised
Before I get started, did you happen to see the MMRF's Kathy Giusti interviewed in the trendy tech magazine, Fast Company? Interesting approach. Simply click-on the headline link below to access the interview: Using Data To Treat Cancer And Drive Innovation How a pair of savvy renegades are forcing collaboration in cancer R&D--and saving lives.
I ended yesterday's post with a flip blip about how Cialis features a precautionary warning specifically naming mutliple myeloma. Ironic, since our good friend, Holt, followed-up with an even stranger Cialis-related email. Turns-out that Cialis (tadalafil) is being tested in ongoing human studies as an anti-multiple meyloma drug! You can't make this stuff up! According
Friday I left everyone hanging when I wrote: Monday I am going to explain how this seemingly mundane result–a 0.2 M-spike–may have been the most fateful news I have ever received as a soon to be six year multiple myeloma survivor. I know I said Monday. But I couldn't resist yesterday's fun and frivolous, self
Thursday afternoon I met with my myeloma specialist, Dr. Melissa Alsina. I have had a standing appointment with her every three months since before I went into remission--and quickly bounced-out ten weeks later--one year ago. But this visit was different. It was to be a fateful one; a turning point. Due to significantly reduced cellularity
A good friend of mine, long-lived myeloma survivor Paula Van Riper, was recently featured in an excellent Wall Street Journal article about the recent FDA approvals of Kyprolis and Pomalyst. The IMF's Medical Director, Dr. Brian Durie, is interviewed, along with Dr. David Siegel, chief of the myeloma division at John Theurer Cancer Center in